Ellen J B Derissen1, Bart A W Jacobs1, Alwin D R Huitema1, Hilde Rosing1, Jan H M Schellens2,3, Jos H Beijnen1,3. 1. Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek Hospital - The Netherlands Cancer Institute and MC Slotervaart, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands. 2. Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. 3. Science Faculty, Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmaco-Epidemiology & Clinical Pharmacology, Utrecht University, P.O. Box 80082, 3508 TB, Utrecht, The Netherlands.
Abstract
AIM: Three intracellularly formed metabolites are responsible for the antineoplastic effect of capecitabine: 5-fluorouridine 5'-triphosphate (FUTP), 5-fluoro-2'-deoxyuridine 5'-triphosphate (FdUTP), and 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP). The objective of this study was to explore the pharmacokinetics of these intracellular metabolites during capecitabine treatment. METHODS: Serial plasma and peripheral blood mononuclear cell (PBMC) samples were collected from 13 patients treated with capecitabine 1000 mg QD (group A) and eight patients receiving capecitabine 850 mg m(-2) BID for fourteen days, every three weeks (group B). Samples were collected on day 1 and, for four patients of group B, also on day 14. The capecitabine and 5-fluorouracil (5-FU) plasma concentrations and intracellular metabolite concentrations were determined using LC-MS/MS. Pharmacokinetic parameters were estimated using non-compartmental analysis. RESULTS: Only FUTP could be measured in the PBMC samples. The FdUTP and FdUMP concentrations were below the detection limits (LOD). No significant correlation was found between the plasma 5-FU and intracellular FUTP exposure. The FUTP concentration-time profiles demonstrated considerable inter-individual variation and accumulation of the metabolite in PBMCs. FUTP levels ranged between <LOD and 1.0 μM on day 1, and from 0.64 to 14 μM on day 14. The area under the FUTP concentration-time curve was significantly increased on day 14 of the treatment compared to day 1 (mean ± SD: 28 ± 19 μM h vs. 2.0 ± 1.9 μM h). CONCLUSIONS: To our knowledge, this is the first time that intracellular FUTP concentrations were measured in patients treated with capecitabine. During 14 days of treatment with capecitabine twice daily, intracellular accumulation of FUTP occurs.
AIM: Three intracellularly formed metabolites are responsible for the antineoplastic effect of capecitabine: 5-fluorouridine 5'-triphosphate (FUTP), 5-fluoro-2'-deoxyuridine 5'-triphosphate (FdUTP), and 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP). The objective of this study was to explore the pharmacokinetics of these intracellular metabolites during capecitabine treatment. METHODS: Serial plasma and peripheral blood mononuclear cell (PBMC) samples were collected from 13 patients treated with capecitabine 1000 mg QD (group A) and eight patients receiving capecitabine 850 mg m(-2) BID for fourteen days, every three weeks (group B). Samples were collected on day 1 and, for four patients of group B, also on day 14. The capecitabine and 5-fluorouracil (5-FU) plasma concentrations and intracellular metabolite concentrations were determined using LC-MS/MS. Pharmacokinetic parameters were estimated using non-compartmental analysis. RESULTS: Only FUTP could be measured in the PBMC samples. The FdUTP and FdUMP concentrations were below the detection limits (LOD). No significant correlation was found between the plasma 5-FU and intracellular FUTP exposure. The FUTP concentration-time profiles demonstrated considerable inter-individual variation and accumulation of the metabolite in PBMCs. FUTP levels ranged between <LOD and 1.0 μM on day 1, and from 0.64 to 14 μM on day 14. The area under the FUTP concentration-time curve was significantly increased on day 14 of the treatment compared to day 1 (mean ± SD: 28 ± 19 μM h vs. 2.0 ± 1.9 μM h). CONCLUSIONS: To our knowledge, this is the first time that intracellular FUTP concentrations were measured in patients treated with capecitabine. During 14 days of treatment with capecitabine twice daily, intracellular accumulation of FUTP occurs.
Authors: Maarten J Deenen; Hilde Rosing; Michel J Hillebrand; Jan H M Schellens; Jos H Beijnen Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2012-12-07 Impact factor: 3.205
Authors: Ellen J B Derissen; Michel J X Hillebrand; Hilde Rosing; Jan H M Schellens; Jos H Beijnen Journal: J Pharm Biomed Anal Date: 2015-03-10 Impact factor: 3.935
Authors: M Miwa; M Ura; M Nishida; N Sawada; T Ishikawa; K Mori; N Shimma; I Umeda; H Ishitsuka Journal: Eur J Cancer Date: 1998-07 Impact factor: 9.162
Authors: G J Peters; J Lankelma; R M Kok; P Noordhuis; C J van Groeningen; C L van der Wilt; S Meyer; H M Pinedo Journal: Cancer Chemother Pharmacol Date: 1993 Impact factor: 3.333
Authors: Sabine Cohen; Mehdi Megherbi; Lars Petter Jordheim; Isabelle Lefebvre; Christian Perigaud; Charles Dumontet; Jérôme Guitton Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2009-09-25 Impact factor: 3.205
Authors: Jeroen Roosendaal; Bart A W Jacobs; Dick Pluim; Hilde Rosing; Niels de Vries; Erik van Werkhoven; Bastiaan Nuijen; Jos H Beijnen; Alwin D R Huitema; Jan H M Schellens; Serena Marchetti Journal: Pharm Res Date: 2020-05-07 Impact factor: 4.200
Authors: Laura Molenaar-Kuijsten; Bart Albertus Wilhelmus Jacobs; Sophie Alberdine Kurk; Anne Maria May; Thomas Petrus Catharina Dorlo; Jacob Hendrik Beijnen; Neeltje Steeghs; Alwin Dagmar Redmar Huitema Journal: Cancer Med Date: 2021-06-14 Impact factor: 4.452